Angeliki Velentza Almpani

Angeliki Velentza Almpani is a highly skilled scientist with extensive experience in cancer research and drug discovery. Currently serving as a Target Discovery Scientist and Clinical Laboratory Scientist at Pear Bio since November 2021, Angeliki focuses on monitoring cancer progression using innovative organ-on-a-chip technology. Previously, as a Research Scientist at Optceutics Limited and during a tenure at The Francis Crick Institute, Angeliki conducted research on RNA networks and protein-protein interactions, contributing to a project aimed at identifying macrocyclic peptides for ALS treatment. Additionally, at the Biomedical Research Foundation of the Academy of Athens, Angeliki evaluated gemcitabine-based analogues for solid tumor therapy. Angeliki holds a Master’s degree in Drug Discovery and Development from Imperial College London and a Bachelor of Science in Chemistry from the National & Kapodistrian University of Athens.